Starling Oncology, Inc.(STLN)

Medical - Care Facilities · Cerritos, CA

$6.58+0.28 (+4.44%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T20:04:29.991Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:04:29.991Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -19,281,000
Quote market capitalization: 657,887,699
Total debt · period ending 2026-06-30: 104,476,000
Cash · period ending 2026-06-30: 41,094,000

FMP input reference: ad03cc2eaddb42082332b148aee8d6851fa015397d59a0785f41cacae5aa3ea4

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

STLN EBITDA Yield Metrics

EBITDA YIELD

N/A

STLN Competitors' EBITDA Yield

STLN

Starling Oncology, Inc.

Current

Market Cap

$657.89M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FDMT

4D Molecular Therapeutics, Inc.

vs STLN

Market Cap

$656.59M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HELP

Helus Pharma Inc.

vs STLN

Market Cap

$666.95M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANNX

Annexon, Inc.

vs STLN

Market Cap

$660.29M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDXG

MiMedx Group, Inc.

vs STLN

Market Cap

$673.41M

EBITDA Yield

3.79%

TTM Avg

10.03%

3Y Avg

6.88%

5Y Avg

6.20%

AURA

Aura Biosciences, Inc.

vs STLN

Market Cap

$638.20M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRME

Prime Medicine, Inc.

vs STLN

Market Cap

$632.16M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SLDB

Solid Biosciences Inc.

vs STLN

Market Cap

$681.27M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ZVRA

Zevra Therapeutics, Inc.

vs STLN

Market Cap

$634.30M

EBITDA Yield

8.26%

TTM Avg

7.14%

3Y Avg

7.14%

5Y Avg

6.31%

VSTM

Verastem, Inc.

vs STLN

Market Cap

$681.02M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Starling Oncology, Inc. (STLN)	$657.89M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$656.59M	N/A	N/A	N/A	N/A
Helus Pharma Inc. (HELP)vs ›	$666.95M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$660.29M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$673.41M	3.79%	10.03%	6.88%	6.20%
Aura Biosciences, Inc. (AURA)vs ›	$638.20M	N/A	N/A	N/A	N/A
Prime Medicine, Inc. (PRME)vs ›	$632.16M	N/A	N/A	N/A	N/A
Solid Biosciences Inc. (SLDB)vs ›	$681.27M	N/A	N/A	N/A	N/A
Zevra Therapeutics, Inc. (ZVRA)vs ›	$634.30M	8.26%	7.14%	7.14%	6.31%
Verastem, Inc. (VSTM)vs ›	$681.02M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

STLN EBITDA Yield Metrics

STLN Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics